Ato Q&A

Ato Q&A is a South Korean biotechnology company specializing in AI-driven drug discovery with a focus on the human microbiome. The company utilizes its proprietary platform, Ato-AI, to analyze vast datasets of microbial information to identify novel therapeutic candidates for inflammatory conditions. Its primary research focus is on skin health, with a lead program targeting atopic dermatitis through the modulation of the skin microbiome. By combining machine learning with microbiology, Ato Q&A aims to streamline the development of live biotherapeutic products and small molecule metabolites. The company was founded by experts from Seoul National University and has secured backing from prominent venture capital firms to advance its precision medicine approach.